MYCEPT is also known as Indian Generic Cellcept, is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. MYCEPT should be used concomitantly with cyclosporine and corticosteroids.
MYCEPT Intravenous is an alternative dosage form to MYCEPT capsules, tablets and oral suspension. MYCEPT Intravenous should be administered within 24 hours following transplantation. MYCEPT Intravenous can be administered for up to 14 days; patients should be switched to oral MYCEPT as soon as they can tolerate oral medication.
CONTRAINDICATIONS
Allergic reactions to MYCEPT have been observed; therefore, MYCEPT is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. MYCEPT Intravenous is contraindicated in patients who are allergic to Polysorbate 80 (TWEEN).
ADVERSE REACTIONS
The principal adverse reactions associated with the administration of MYCEPT include diarrhea, leukopenia, sepsis, vomiting, and there is evidence of a higher frequency of certain types of infections eg, opportunistic infection. The adverse event profile associated with the administration of MYCEPT Intravenous has been shown to be similar to that observed after administration of oral dosage forms of MYCEPT.
MYCEPT’s brand name in usa is CellCept by Roche. MYCEPT is a generic prescription medicine from Panacea Biotech, which is one of the biggest pharmaceutical company in India.
